Evidence map›Paper›PMID 35651787›Full record

ArticleFrontiers in oncology2022

RRM2 Mediates the Anti-Tumor Effect of the Natural Product Pectolinarigenin on Glioblastoma Through Promoting CDK1 Protein Degradation by Increasing Autophagic Flux.

Haiping Jiang, Dongzhi Zhang, Karpov Denis Aleksandrovich, Junyi Ye, Lixiang Wang, Xiaofeng Chen, Ming Gao, Xinzhuang Wang, Tao Yan, He Yang and 12 more

Open access · goldAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Frontiers in oncology, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 10 papers.

0numbers the graph read from it
0cells of the map it votes in
10citing papers in PubMed
3.1field-weighted citation impact, top 8% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

10 citing papers in PubMed, 21 citations in OpenAlex.

  1. Targeting Cancer Hallmarks withInternational journal of molecular sciences · 2026
    Review
  2. Article
  3. Article
  4. Article
  5. Article
  6. Article
  7. Article
  8. Article
  9. Article
  10. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

22 authors at 2 institutions in 3 countries.

Haiping JiangDepartment of Neurosurgery, The First Affiliated Hospital of Harbin Medical University, Harbin, China.
Dongzhi ZhangDepartment of Neurosurgery, The First Affiliated Hospital of Harbin Medical University, Harbin, China.
Karpov Denis AleksandrovichDepartment of Neurosurgery, The First Affiliated Hospital of Harbin Medical University, Harbin, China.
Junyi YeDepartment of Neurosurgery, The First Affiliated Hospital of Harbin Medical University, Harbin, China.
Lixiang WangDepartment of Neurosurgery, The First Affiliated Hospital of Harbin Medical University, Harbin, China.
Xiaofeng ChenDepartment of Neurosurgery, The First Affiliated Hospital of Harbin Medical University, Harbin, China.
Ming GaoDepartment of Neurosurgery, The First Affiliated Hospital of Harbin Medical University, Harbin, China.
Xinzhuang WangDepartment of Neurosurgery, The First Affiliated Hospital of Harbin Medical University, Harbin, China.
Tao YanDepartment of Neurosurgery, The First Affiliated Hospital of Harbin Medical University, Harbin, China.
He YangDepartment of Neurosurgery, The First Affiliated Hospital of Harbin Medical University, Harbin, China.
Enzhou LuDepartment of Neurosurgery, The First Affiliated Hospital of Harbin Medical University, Harbin, China.
Wenwu LiuDepartment of Neurosurgery, The First Affiliated Hospital of Harbin Medical University, Harbin, China.
Cheng ZhangDepartment of Undergraduate, Suffolk University, Boston, MA, United States.
Jianing WuDepartment of Neurosurgery, Shenzhen University General Hospital, Shenzhen, China.
Penglei YaoDepartment of Neurosurgery, Shenzhen University General Hospital, Shenzhen, China.
Zhenying SunDepartment of Neurosurgery, Shenzhen University General Hospital, Shenzhen, China.
Xuan RongDepartment of Neurosurgery, Shenzhen University General Hospital, Shenzhen, China.
Sokhatskii Andrei TimofeevichDepartment of Neurosurgery, The First Affiliated Hospital of Harbin Medical University, Harbin, China.
Safin Shamil MahmutovichDepartment of Neurosurgery and Medical Rehabilitation, Bashkir State Medical University, Ufa, Russia.
Zhixing ZhengDepartment of Neurosurgery, The First Affiliated Hospital of Harbin Medical University, Harbin, China.
Xin ChenDepartment of Neurosurgery, The First Affiliated Hospital of Harbin Medical University, Harbin, China.
Shiguang ZhaoDepartment of Neurosurgery, The First Affiliated Hospital of Harbin Medical University, Harbin, China.
Harbin Medical University · CNShenzhen University · CN

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

The natural product pectolinarigenin exerts anti-inflammatory activity and anti-tumor effects, and exhibits different biological functions, particularly in autophagy and cell cycle regulation. However, the antineoplastic effect of pectolinarigenin on glioblastoma (GBM) remains unclear. In the present study, we found that pectolinarigenin inhibits glioblastoma proliferation, increases autophagic flux, and induces cell cycle arrest by inhibiting ribonucleotide reductase subunit M2 (RRM2), which can be reversed by RRM2 overexpression plasmid. Additionally, pectolinarigenin promoted RRM2 protein degradation

Indexed as

autophagic fluxCDK1glioblastomapectolinarigeninRRM2

Identifiers

PMID35651787
PMCPMC9150261
OpenAlexW4280544515

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.